The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
- 879 Downloads
Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS).
This study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial.
This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia. All subjects completed the MATRICS Consensus Cognitive Battery (MCCB) at baseline and at end of 6 weeks of treatment. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and biweekly.
There was no main effect of time or drug on MCCB Composite score, but a significant drug × time effect was observed (p = 0.02). Post hoc analyses revealed that only placebo-treated subjects improved over time (p = 0.03). There was a significant decrease in PANSS Total scores over time (p < 0. 0001) but there was no significant drug × time interaction (p = 0.18). Side effects were similar between CBD and placebo, with the one exception being sedation, which was more prevalent in the CBD group.
At the dose studied, CBD augmentation was not associated with an improvement in MCCB or PANSS scores in stable antipsychotic-treated outpatients with schizophrenia. Overall, CBD was well tolerated with no worsening of mood, suicidality, or movement side effects.
KeywordsCannabidiol CBD Cannabinoids Schizophrenia Psychosis Cognition Memory Attention
Compliance with ethical standards
Conflict of interest
Support granted by the Stanely Medical Research Institute.
Mohini Ranganathan has in the past 3 years or currently received research grant support administered through Yale University School of Medicine from Insys Therapeutics and Pfizer Inc. Deepak Cyril D’Souza has in the past 3 years or currently received research grant support administered through Yale University School of Medicine from Pfizer Inc. Pfizer, Inc. had a role in the design and conduct of the study: collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and the decision to submit the manuscript for publication. Andrew Davies is a founder and full time employee of STI Pharmaceuticals Ltd (UK). Douglas Boggs, Aarti Gupta, John Cahill, Brian Pittman, Ashley Schnakenberg Martin, Halle Thurnauer, Swapnil Gupta, and Toral Surti report no financial relationships with commercial interests.
- Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O'Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 35:764–774CrossRefGoogle Scholar
- Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW (2010) AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58:365–373CrossRefPubMedGoogle Scholar
- D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 29:1558–1572CrossRefGoogle Scholar
- D’Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C (2013) Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 38:492–503CrossRefGoogle Scholar
- ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A (2017) Phytochemistry of Cannabis sativa L Phytocannabinoids. In: Kinghorn AD, Falk H, Gibbons S, Kobayashi J (eds) Progress in the chemistry of organic natural products, vol. 103. Phytocannabinoids: unraveling the complex chemistry and pharmacology of Cannabis sativa. Springer International Publishing, New York, pp 1–36Google Scholar
- Fagherazzi EV, Garcia VA, Maurmann N, Bervanger T, Halmenschlager LH, Busato SB, Hallak JE, Zuardi AW, Crippa JA, Schroder N (2012) Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology 219:1133–1140CrossRefPubMedGoogle Scholar
- Guy W (1976) Abnormal involuntary movement scale (AIMS). ECDEU Assess Manual Psychopharmacol 338:534–537Google Scholar
- Hallak JE, Machado-de-Sousa JP, Crippa JA, Sanches RF, Trzesniak C, Chaves C, Bernardo SA, Regalo SC, Zuardi AW (2010) Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr 32:56–61CrossRefPubMedGoogle Scholar
- Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, del Miller D, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA (2006) Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31:2033–2046CrossRefPubMedGoogle Scholar
- Murphy M, Mills S, Winstone J, Leishman E, Wager-Miller J, Bradshaw H, Mackie K (2017) Chronic adolescent Δ9-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment. Cannabis Cannabinoid Res 2:235–246CrossRefPubMedPubMedCentralGoogle Scholar
- Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR (2008) The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165:203–213CrossRefPubMedGoogle Scholar
- O’Donnell CJ, Rogers BN, Bronk BS, Bryce DK, Coe JW, Cook KK, Duplantier AJ, Evrard E, Hajos M, Hoffmann WE, Hurst RS, Maklad N, Mather RJ, McLean S, Nedza FM, O’Neill BT, Peng L, Qian W, Rottas MM, Sands SB, Schmidt AW, Shrikhande AV, Spracklin DK, Wong DF, Zhang A, Zhang L (2010) Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models. J Med Chem 53:1222–1237CrossRefPubMedGoogle Scholar
- Riedel G, Davies SN (2005) Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 168:445–477Google Scholar
- Rund BR, Melle I, Friis S, Larsen TK, Midboe LJ, Opjordsmoen S, Simonsen E, Vaglum P, McGlashan T (2004) Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry 161:466–472CrossRefPubMedGoogle Scholar
- Wechsler D (1955) Manual: Wechsler adult intelligence scale. Psychological Corp, New YorkGoogle Scholar
- Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fornito A, Wood SJ, McGorry PD, Pantelis C (2012) The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 38:316–330CrossRefPubMedGoogle Scholar
- Zuardi AW, Guimaraes FS, Moreira AC (1993) Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res 26:213–217Google Scholar